UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2008
BioCryst Pharmaceuticals,
Inc.
(Exact name of registrant as
specified in its charter)
| Delaware | 000-23186 | 62-1413174 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 2190 Parkway Lake Drive, Birmingham, Alabama | 35244 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (205) 444-4600
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors on Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers
On May 21, 2008, the Compensation Committee of the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved bonuses for the following executive officers, vesting and payable on December 31, 2009 as shown below.
| Restricted Stock Awards | ||||||||||||
| Executive Officer | Bonus | Shares | Value as of 5/21/08 | |||||||||
|
Stuart Grant, Senior VP,
CFO
|
$ | 309,000 | 24,839 | $ | 77,498 | |||||||
|
David McCullough, VP
Strategic Development and Commercialization
|
$ | 179,616 | 14,439 | $ | 45,050 | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 28, 2008 | BioCryst Pharmaceuticals, Inc. | |||
|
|
||||
|
|
||||
|
|
By: | /s/ Michael A. Darwin | ||
|
|
||||
|
|
Michael A. Darwin | |||
|
|
VP Finance and Principal Accounting Officer |
|||